Novartis presents new long-term Leqvio® (inclisiran) da

Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipo...

Related Keywords

United States , South Korea , Amsterdam , Noord Holland , Netherlands , China , America , Han , American , David Soergel , Novartis Leqvio , Sloan Simpson , Michael Meo Marlena Abdinoor , Coll Cardiol , Julie Masow , Los Angeles , Norman Lepor , Metabolic Drug Development , Exchange Commission , Public Health , Twitter , Congress On , Novartis Pharmaceuticals Corporation , American Heart Association , European Union , National Cholesterol Education Program , European Medicines Agency , National Medical Products Administration , World Health Organization , Novartis , Alnylam Pharmaceuticals , Vasc Health Risk Manag , Drug Administration , Impact Of Lipids On Cardiovascular Health , Health Promotion Series , National Heart Institute , European Society Of Cardiology , Expert Panel On Detection , European Society , National Heart , Global Head , Safety Information , Heterozygous Familial , Wide Cross Sectional Observational Study , Lipid Modifying Therapy Use , Primary Care , Accessed July , Medicines Agency , Medical Products Administration , Accessed August , Health Risk , High Cardiovascular Risk , Cardiovascular Health , Health Organization , Published June , American Heart , Cholesterol Education Program , Expert Panel , High Blood Cholesterol , Adult Treatment Panel , Third Report , Media Relationse Mail , Investor Relationse Mail ,